Propanc Health Group Corp (OTCMKTS:PPCH) a growing healthcare company said it has raised capital of $468,500 from institutional investors in 2015, with $532,500 in additional capital commitments. The capital realized from financing will be used in completion of the next stage of animal trials which are necessary for entry into human studies and commencement of licensing talks for its lead product, PRP.
The significance of studies
Propanc Health said that there trials are vital as the company is evaluating I.V administration of PRP. Dr Julian Kenyon, the CSO said that the team believes that the medication will result in a more powerful anti-cancer effect by increasing exposure of the drug to tumors. This particular route of administration differs from a proenzyme medication by suppository for compassionate use. In this case it is possible for terminally ill patients to self-administer treatment. The drug can be absorbed into the bloodstream to put forth its effects and preventing breakdown in the gut.
Professor Klaus Kutz, the Chief Medical Officer of Propanc Health Group Corp (OTCMKTS:PPCH), said that these trials will offer valuable data relating to the tolerability and safety of PRP. It will also test efficacy as medication is administered by I.V Injection. He further added that at the same time his retrospective review of patients indicated that a proenzyme medication has the potential to significantly extend life. It is free from serious side effects that are normally linked with standard therapies. The company is determined to fully evaluate the behavior of the drug candidate in animals prior to starting human trials.
Propanc Health was afloated by trading activity of its stock in past weeks, and as a result, witnessed several analysts analyzing the Company’s future plans more closely. James Nathanielsz, the Chief Executive Officer, said that the company welcome scrutiny from experts and agree investors should examine a company before making an investment decision.
In last trading session, PPCH stock surged 2.33% to close at $0.0154 with 6.59 million shares traded.